Atopic Asthma Clinical Trial
Official title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess The Safety and Efficacy of Two Weeks of Oral Senicapoc Administration on Allergen Challenge in Atopic Asthmatic Subjects
The purpose of the study is to determine whether senicapoc can decrease changes in FEV1 following allergen challenge in atopic allergic subjects.
Based on the unmet medical need for new agents in the treatment of asthma and the role of KCa3.1 in the function of several different cell types involved in the inflammatory response, and the effects seen in an animal model of allergic asthma, it is reasonable to explore the utility of senicapoc, a KCa3.1 blocker, as a novel treatment of asthma. This study will test the ability of senicapoc to alleviate bronchospasm induced by an allergen challenge in patients with allergic asthma. It is analogous to the study performed in animals in which senicapoc demonstrated the ability to reduce airway resistance and hyper-responsiveness induced by airway challenge with antigen and carbachol, respectively. This study is also the first to test the ability of senicapoc to reduce airway inflammation, which is the key pathophysiologic process in asthma. In summary, with a demonstrated safety profile across a wide range of doses in humans and efficacy in an animal model of allergic bronchospasm and hyper-responsiveness, the initiation of exploratory studies of senicapoc for treatment of asthma is justified. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01448954 -
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma
|
Phase 2 | |
| Withdrawn |
NCT01049178 -
Randomized Controlled Trial of Silymarin in Asthma
|
Phase 2/Phase 3 | |
| Terminated |
NCT00644514 -
Genetics of Asthma - Bronchoscopy Studies
|
Phase 1 | |
| Completed |
NCT00784459 -
The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics
|
Phase 2 | |
| Terminated |
NCT00671593 -
Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge
|
Phase 1 | |
| Completed |
NCT05098600 -
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
|
||
| Completed |
NCT01420003 -
Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics
|
N/A | |
| Completed |
NCT02758548 -
Determination of Accuracy in Measurement of Total Immunoglobulin E Using a Test Device in Atopic Subjects
|
Phase 2 | |
| Completed |
NCT01179256 -
Effect of Supplemental Oral Curcumin in Patients With Atopic Asthma
|
N/A | |
| Completed |
NCT01545245 -
Effects of Preventive Treatment for Respiratory Syncytial (RS) Virus Infection During Infancy on Later Atopic Asthma in Preterm Infants
|
N/A | |
| Completed |
NCT03603522 -
Probiotics and Capsaicin Evoked Coughs
|
N/A | |
| Completed |
NCT04728711 -
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)
|
Phase 2 | |
| Recruiting |
NCT03928431 -
Restoration of Microbiota in Neonates
|
N/A | |
| Completed |
NCT02327234 -
Airway Response to Repeat Allergen Challenge and the Effect of Ibuprofen in Mild Atopic Asthma
|
N/A | |
| Completed |
NCT01890161 -
A Phase IIa Repeat Dose AXP1275 vs Placebo Cross-over Trial With Pulmonary Allergen Challenge in Adults With Asthma
|
Phase 2 | |
| Completed |
NCT03665701 -
Characterization of the Inhibitory Effects of Fevipiprant (QAW039) on Activation of Eosinophils and ILC2 Cells by Prostaglandin D2 Metabolites
|
N/A | |
| Completed |
NCT04397081 -
Atopic Diseases & Human Papilloma Virus
|